Evaluation of Tiotropium 5 µg/Day Delivered Via the Respimat® Inhaler Over 48 Weeks in Patients With Severe Persistent Asthma on Top of Usual Care (Study I)
PHASE3
The trial is a randomised, double-blind, placebo-controlled, parallel-group...
Status
Completed
Location
205.416.01007 Boehringer Ingelheim Investigational Site
A Study to Test the Combination of Tiotropium and Olodaterol Using the Respimat® Inhaler in People With Chronic Obstructive Pulmonary Disease (COPD) Who Have Different Abilities to Inhale
PHASE4
To demonstrate the efficacy of inhaled tiotropium + olodaterol via Respimat...
Study on BI 54903 (Inhaled Corticosteroid) Administered Once Daily or Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Short Acting Beta-2 Agonist (SABA) Therapy Alone
PHASE2
The aim of this study is to assess and compare efficacy and safety of BI 54...
Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo in 1 to 5 Year Old Patients With Persistent Asthma
PHASE2
The primary objective of this trial is to evaluate the safety and efficacy ...
Status
Completed
Location
205.443.12003 Boehringer Ingelheim Investigational Site
Randomised, Double- Blind, Cross-over Efficacy and Safety Comparison of Three Different Doses of Tiotropium Administered Once Daily Versus Placebo in Patients With Moderate Persistent Asthma.
PHASE2
Rationale for the current trial is to evaluate the efficacy and safety of t...
Status
Completed
Location
205.380.43002 Boehringer Ingelheim Investigational Site
Comparison of Two Daily Dose Regimens of Tiotropium 5 µg Once Daily and Tiotropium 2.5 µg Twice Daily for 4 Weeks on Top of Maintenance Therapy With Inhaled Corticosteroid Controller Medication
PHASE2
Determine the 24-hour FEV1-profile of tiotropium solution for inhalation af...
Status
Completed
Location
205.441.43004 Boehringer Ingelheim Investigational Site